175 related articles for article (PubMed ID: 38328802)
1. Long-term efficacy of house dust mite sublingual immunotherapy on clinical and pulmonary function in patients with asthma and allergic rhinitis.
Hoshino M; Akitsu K; Ohtawa J; Kubota K
J Allergy Clin Immunol Glob; 2024 May; 3(2):100206. PubMed ID: 38328802
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a house dust mite sublingual immunotherapy tablet as add-on dupilumab in asthma with rhinitis.
Hoshino M; Akitsu K; Kubota K; Ohtawa J
Allergol Int; 2022 Oct; 71(4):490-497. PubMed ID: 35718711
[TBL] [Abstract][Full Text] [Related]
3. Association between biomarkers and house dust mite sublingual immunotherapy in allergic asthma.
Hoshino M; Akitsu K; Kubota K; Ohtawa J
Clin Exp Allergy; 2020 Sep; 50(9):1035-1043. PubMed ID: 32557974
[TBL] [Abstract][Full Text] [Related]
4. Effect of Sublingual Immunotherapy on Airway Inflammation and Airway Wall Thickness in Allergic Asthma.
Hoshino M; Akitsu K; Kubota K
J Allergy Clin Immunol Pract; 2019; 7(8):2804-2811. PubMed ID: 31228618
[TBL] [Abstract][Full Text] [Related]
5. Serum Periostin as a Biomarker for Predicting Clinical Response to House Dust Mite Sublingual Immunotherapy in Allergic Rhinitis.
Hoshino M; Akitsu K; Kubota K; Ohtawa J
J Allergy Clin Immunol Pract; 2021 May; 9(5):1864-1870. PubMed ID: 33290915
[TBL] [Abstract][Full Text] [Related]
6. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
Virchow JC; Backer V; Kuna P; Prieto L; Nolte H; Villesen HH; Ljørring C; Riis B; de Blay F
JAMA; 2016 Apr; 315(16):1715-25. PubMed ID: 27115376
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Sublingual Immunotherapy in the Treatment of HDM-Induced Nasobronchial Allergies: A 3-Year Randomized Case-Control Study From Kashmir.
Baba SM; Rasool R; Gull A; Qureshi TA; Beigh AH; Qadri Q; Shah ZA
Front Immunol; 2021; 12():723814. PubMed ID: 34721385
[TBL] [Abstract][Full Text] [Related]
9. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S
J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy comparison and safety analysis of subcutaneous specific immunotherapy with standardized house dust mite allergen in patients with single and multiple allergic rhinitis].
Huang HH; Xu C; Liu L; Chai RN
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jun; 56(6):774-783. PubMed ID: 35785859
[No Abstract] [Full Text] [Related]
12. Serum Soluble ST2 Correlated with Symptom Severity and Clinical Response of Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis Patients.
Zhu K; Xia C; Chen J; Yu C; Gao T; Yan J; Shao N; Zhu P; Sun B; Ren X; Zhang Y
Mediators Inflamm; 2021; 2021():5576596. PubMed ID: 34194284
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of House Dust Mite Sublingual Immunotherapy Tablet in Allergic Asthma: A Systematic Review of Randomized Controlled Trials.
Wongsa C; Phinyo P; Sompornrattanaphan M; Krikeerati T; Lumkul L; Thongngarm T
J Allergy Clin Immunol Pract; 2022 May; 10(5):1342-1355.e24. PubMed ID: 35181547
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial.
Karakoc-Aydiner E; Eifan AO; Baris S; Gunay E; Akturk E; Akkoc T; Bahceciler NN; Barlan IB
J Investig Allergol Clin Immunol; 2015; 25(5):334-42. PubMed ID: 26727762
[TBL] [Abstract][Full Text] [Related]
15. Circulating MIF Associated With Disease Severity and Clinical Response of Sublingual Immunotherapy in House Dust Mite-Induced Allergic Rhinitis.
Xie S; Zhang H; Wang F; Xie Z; Jiang W; Gao K
Front Pharmacol; 2021; 12():681724. PubMed ID: 34305594
[No Abstract] [Full Text] [Related]
16. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.
Demoly P; Emminger W; Rehm D; Backer V; Tommerup L; Kleine-Tebbe J
J Allergy Clin Immunol; 2016 Feb; 137(2):444-451.e8. PubMed ID: 26292778
[TBL] [Abstract][Full Text] [Related]
17. House Dust Mite Sublingual Immunotherapy for Pediatric Patients With Allergic Asthma.
Richards JR; Stumpf JL
Ann Pharmacother; 2018 Oct; 52(10):1019-1030. PubMed ID: 29642713
[TBL] [Abstract][Full Text] [Related]
18. The effects of house dust mite sublingual immunotherapy in patients with allergic rhinitis according to duration.
Lin Z; Liu Q; Li T; Chen D; Chen D; Xu R
Int Forum Allergy Rhinol; 2016 Jan; 6(1):82-7. PubMed ID: 26575696
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial.
Eifan AO; Akkoc T; Yildiz A; Keles S; Ozdemir C; Bahceciler NN; Barlan IB
Clin Exp Allergy; 2010 Jun; 40(6):922-32. PubMed ID: 20100188
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Sublingual Immunotherapy in Elderly Rhinitis Patients Sensitized to House Dust Mites.
Kim JH; Lee JH; Ye YM; Lee JH; Park JW; Hur GY; Kim JH; Lee HY; Shin YS; Yang EM; Park HS
Allergy Asthma Immunol Res; 2018 Nov; 10(6):675-685. PubMed ID: 30306749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
